preclinical Alzheimer's disease

From Aaushi
Jump to navigation Jump to search

Introduction

Terms created for research purposes.

Etiology

* genetic markers are not included

Clinical manifestations

  • missing bill payments & other financial mistakes[10]

Diagnostic criteria

NINCDS-ADRDA criteria:

  • asymptomatic

Laboratory

* also see laboratory investigation of Alzheimer's disease

Diagnostic procedures

* GPS: global positioning system

Radiology

* also see radiology of Alzheimer's disease

Complications

Management

More general terms

References

  1. Geriatric Review Syllabus, 8th edition (GRS8) Durso SC and Sullivan GN (eds) American Geriatrics Society, 2013
  2. Sperling RA, Aisen PS, Beckett LA et al Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging- Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011 May;7(3):280-92. PMID: https://www.ncbi.nlm.nih.gov/pubmed/21514248
  3. 3.0 3.1 George J Eyes Might ID Preclinical Alzheimer's. Presymptomatic patients show foveal thinning, retinal changes. MedPage Today. April 24, 2018 https://www.medpagetoday.com/meetingcoverage/aan/72508
    Van Stavern G, et al Optical coherence tomography angiography in pre-clinical Alzheimer's disease. American Academy of Neurology (AAN) 2018.
  4. 4.0 4.1 George J. Most Preclinical AD Doesn't Progress to Dementia. Model is the first to include biomarkers in lifetime Alzheimer's dementia risk. MedPage Today. May 22, 2018 https://www.medpagetoday.com/neurology/alzheimersdisease/73046
    Brookmeyer R, Abdalla N Estimation of lifetime risks of Alzheimer's disease dementia using biomarkers for preclinical disease. Alzheimer's & Dementia 2018; PMID: https://www.ncbi.nlm.nih.gov/pubmed/29802030
  5. Brookmeyer R, Abdalla N, Kawas CH, Corrada MM. Forecasting the prevalence of preclinical and clinical Alzheimer's disease in the United States. Alzheimers Dement. 2018 Feb;14(2):121-129. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29233480
  6. 6.0 6.1 Rabin JS, Schultz AP, Hedden T et al Interactive Associations of Vascular Risk and beta-Amyloid Burden With Cognitive Decline in Clinically Normal Elderly Individuals. Findings From the Harvard Aging Brain Study. JAMA Neurol. Published online May 21, 2018 PMID: https://www.ncbi.nlm.nih.gov/pubmed/29799986 https://jamanetwork.com/journals/jamaneurology/fullarticle/2680896
  7. 7.0 7.1 Langa KM, Burke JF. Preclinical Alzheimer Disease - Early Diagnosis or Overdiagnosis? JAMA Intern Med. Published online July 8, 2019 PMID: https://www.ncbi.nlm.nih.gov/pubmed/31282928 Free PMC Article https://jamanetwork.com/journals/jamainternalmedicine/fullarticle/2737753
  8. 8.0 8.1 Rabin JS, Klein H, Kirn DR et al Associations of Physical Activity and beta-Amyloid With Longitudinal Cognition and Neurodegeneration in Clinically Normal Older Adults. JAMA Neurol. Published online July 16, 2019. PMID: https://www.ncbi.nlm.nih.gov/pubmed/31312836 https://jamanetwork.com/journals/jamaneurology/fullarticle/2738357
  9. 9.0 9.1 9.2 George J Driving Patterns Pinpoint Early Alzheimer's Disease. Subtle shifts in on-road behavior suggest GPS-based biomarkers may have merit. MedPage Today July 30, 2021 https://www.medpagetoday.com/meetingcoverage/aaic/93840
    Bayat S, Babulal GM., Schindler SE et al. GPS driving: a digital biomarker for preclinical Alzheimer disease. Alz Res Therapy 2021 13, 115 https://alzres.biomedcentral.com/articles/10.1186/s13195-021-00852-1
  10. 10.0 10.1 Nicholas LH, Langa KM, Bynum JP et al Financial Presentation of Alzheimer Disease and Related Dementias. JAMA Intern Med. 2021;181(2):220-227. PMID: https://www.ncbi.nlm.nih.gov/pubmed/33252621 https://jamanetwork.com/journals/jamainternalmedicine/article-abstract/2773241
  11. 11.0 11.1 Young CB, Winer JR, Younes K et al Divergent Cortical Tau Positron Emission Tomography Patterns Among Patients With Preclinical Alzheimer Disease. JAMA Neurol. Published online April 18, 2022 PMID: https://www.ncbi.nlm.nih.gov/pubmed/35435938 https://jamanetwork.com/journals/jamaneurology/fullarticle/2790807
  12. 12.0 12.1 George J Blood Test Predicts Which People With Amyloid Are Likely to Decline Cognitively. Plasma p-tau217 outperformed other preclinical Alzheimer's measures. MedPage Today February 6, 2023 https://www.medpagetoday.com/neurology/alzheimersdisease/102970
    Mattsson-Carlgren N, Salvado G, Ashton NJ et al Prediction of Longitudinal Cognitive Decline in Preclinical Alzheimer Disease Using Plasma Biomarkers. JAMA Neurol. Published online February 6, 2023 PMID: https://www.ncbi.nlm.nih.gov/pubmed/36745413 https://jamanetwork.com/journals/jamaneurology/fullarticle/2801289